Compare Abbott Laboratories (ABT) vs Krispy Kreme Inc (DNUT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Krispy Kreme Inc — how do they compare? Abbott Laboratories trades at $95.16 (market cap $166.94B), while Krispy Kreme Inc trades at $3.46 (market cap $572.37M). The key difference: Abbott Laboratories is far larger — about 291.7× Krispy Kreme Inc's market cap, and Krispy Kreme Inc pays the higher dividend (3.47%). Which is the better fit depends on your goals.
| ABT | DNUT | |
|---|---|---|
Market Cap | $166.94B | $572.37M |
Sector | Health | Consumer Staples |
52-Week High | $136.62 | $4.70 |
52-Week Low | $82.57 | $2.92 |
Enterprise Value | $193.69B | $1.77B |
Dividend Yield | 2.63% | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Krispy Kreme (DNUT) trades at $3.32, down 5.41% today, with a bearish technical signal and neutral oscillators. The company reported Q1 2026 EPS of -$0.05, missing expectations, though Q4 2025 and Q3 2025 beat estimates. Revenue for 2025 was $1.52B with a net loss of -$515.77M, reflecting a -33.36% net margin. Analyst consensus is 50% buy, 35.71% hold, and 14.29% sell. Recent news highlights automation efforts and new product launches to attract younger consumers.
The outlook remains challenging with persistent losses and high debt, but strategic pivots to capital-light models and international growth offer potential. Risks include execution missteps and competitive pressures. Investors should weigh turnaround progress against financial instability, with Q2 2026 earnings on August 6, 2026, as a key catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Krispy Kreme Inc
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →
